Insulin glargine in combination with nateglinide in people with Type 2 diabetes: A randomized placebo-controlled trial

Diabetic Medicine

Volumn 24, Issue 4, 2007, Pages 344-349

  Dashora, U K ^a,b   Sibal, L ^a   Ashwell, S G ^a   Home, P D ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b St Leonards on Sea   (United Kingdom)

Author keywords

Insulin glargine; Nateglinide; Type 2 diabetes

Indexed keywords

GLUCOSE; INSULIN GLARGINE; METFORMIN; NATEGLINIDE; OPTIPEN PRO; ORAL ANTIDIABETIC AGENT; PLACEBO; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CAPILLARY BLOOD; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SELF MONITORING; STATISTICAL ANALYSIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CYCLOHEXANES; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; PHENYLALANINE; TIME FACTORS;

EID: 33947378841     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02094.x     Document Type: Article

References (29)

1. United Kingdom Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
2. Ohkubo Y, Kishikawa H, Araki E. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
3. Matthews D, Pfeiffer C. A new long-acting insulin (HOE 901) demonstrates less nocturnal hypoglycaemia when compared with protamine insulin in a clinical trial. Diabetologia 1998; 41: A245.
4. Rosenstock J, Schwartz S, Clark C, Park G, Donley D, Edward M. Basal insulin therapy in Type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH. Diabetes Care 2001; 24: 631-636.
5. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycaemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in Type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000; 23: 1130-1136.
6. Fritsche A, Schweitzer MA, Haring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with Type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003; 138: 952-959.
7. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of Type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
8. Ryysy L, Yki-Järvinen H, Hänninen J, Hulme S, Kauppinen-Mäkelin R, Lahdenperä S et al. Simplifying treat to target - the LANMET study. Diabetologia 2004; 47: A271.
9. Monnier L. Is postprandial glucose a neglected cardiovascular risk factor in Type 2 diabetes? Eur J Clin Invest 2000; 30: 3-11.
10. Del Prato S. Post-prandial hyperglycaemias: the necessity for better control. Int J Clin Pract 2000; 12: 3-8.
11. Ceriello A. The emerging role of postprandial hyperglycaemic spikes in the pathogenesis of diabetic complications. Diabet Med 1998; 15: 188-193.
12. Home PD. Postprandial hyperglycaemia: mechanisms and importance. Diabetes Obes Metab 2000; 2: S7-11.
13. Ceriello A. Postprandial hyperglycaemia and diabetes complications. Diabetes 2005; 54: 1-7.
14. Heine RJ, Balkau B, Ceriello A, Del Prato S, Horton ES, Taskinen MJ. What does postprandial hyperglycaemia mean? Diabet Med 2004; 21: 208-213.
15. DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617-621.
16. DECODE Study Group for the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405.
17. Gerstein HC. Is glucose a continuous risk factor for cardiovascular mortality? Diabetes Care 1999; 22: 659-660.
18. Balkau B, Bertrais S, Ducimetiere P, Eschwege E. Is there a glycemic threshold for mortality risk? Diabetes Care 1999; 22: 696-9.
19. Haffner S. The importance of hyperglycaemia in the non-fasting state to the development of cardiovascular disease. Endocr Rev 1998; 19: 583-592.
20. Perry RC, Baron A. Impaired glucose tolerance: why is it not a disease? Diabetes Care 1992; 22: 883-885.
21. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
22. Gribble FM, Manley SE, Levy JC. Randomized dose ranging study of the reduction of fasting and postprandial glucose in Type 2 diabetes by nateglinide (A-4166). Diabetes Care 2001; 24: 1221-1225.
23. Hirschberg Y, Karara AH, Pietri AO, McLeod JF. Improved control of mealtime glucose excursions with co-administration of nateglinide and metformin. Diabetes Care 2000; 23: 349-353.
24. Rosenstock J, Park G, Zimmerman J, for the US Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Basal insulin glargine (HOE 901) versus NPH insulin in patients with Type 1 diabetes on multiple daily insulin regimens. Diabetes Care 2000; 23: 1137-1142.
25. Pieber TR, Eugene-Jolchine I, Derobert E and the European Study Group of HOE 901 in Type 1 diabetes. Efficacy and safety of HOE 901 versus NPH insulin in patients with Type 1 diabetes. Diabetes Care 2000; 23: 157-162.
26. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for Type 2 diabetes. Diabetes Care 2005; 28: 254-259.
27. Damsbo P, Clauson P, Marbury TC, Windfeld K. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled Type 2 diabetic patients. Diabetes Care 1999; 22: 789-794.
28. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R. Initiation of glargine in Type 2 patients with suboptimal glycaemic control on twice-daily premix insulin: results from the AT:LANTUS trial. Diabetologia 2004; 47: A146.
29. Dashora U, Ashwell S, Hilberg C, Vaz J, Home PD. Thrice daily treatment with high-ratio biphasic insulin aspart improves lunch-time postprandial glucose control compared with twice daily treatment with low ratio biphasic human insulin in people with Type 2 diabetes. Diabetes 2004; 53: A473.